2 completed, 2 recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow SPARK Biopharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects SB17170, SB_MDZ - Drug Drug Interaction (DDI) | Phase 1 | Completed | SPARK Biopharma | 12 | 2025-03-27 | 2025-11-19 |
| SB17170 Phase 2 Trial in IPF Patients SB17170, Placebo - IPF, Idiopathic Pulmonary Fibrosis | Phase 2 | Recruiting | SPARK Biopharma | 30 | 2025-01-27 | 2025-11-19 |
| SB17170 Phase1 Trial in Healthy Volunteer SB17170, Placebo - Safety Issues, Tolerability | Phase 1 | Completed | SPARK Biopharma | 64 | 2023-05-24 | 2024-03-21 |
| SB17170 Phase 1 Clinical Trial in Solid Tumors SB17170 - Solid Tumor | Phase 1 | Recruiting | SPARK Biopharma | 50 | 2022-10-17 | 2025-11-20 |
Idiopathic Pulmonary Fibrosis (1)
South Korea (4)
SeungHwan Lee, M.D. (1) · Soojin Jun (1)